Filana Therapeutics, Inc. Accounts Payable and Other Accrued Liabilities, Current
Filana Therapeutics, Inc. (FLNA) had Accounts Payable and Other Accrued Liabilities, Current of $39.19 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-05-07
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $39.19M.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $41.65M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $46.09M.
- 2025-06-30: Accounts Payable and Other Accrued Liabilities, Current $42.82M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2026-03-31 | $39.19M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $41.65M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $46.09M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $42.82M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $8.19M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $7.65M 10-K · filed 2026-03-12 |
| 2024-09-30 | $52.24M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $52.55M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $9.60M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $10.57M 10-K · filed 2025-03-03 |
| 2023-09-30 | $9.49M 10-Q · filed 2023-11-07 |
| 2022-12-31 | $4.02M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |